Taams Leonie S, Palmer Donald B, Akbar Arne N, Robinson Douglas S, Brown Zarin, Hawrylowicz Catherine M
Division of Infection, Immunity and Inflammatory Diseases, Guy's Hospital, King's College London, London, UK.
Immunology. 2006 May;118(1):1-9. doi: 10.1111/j.1365-2567.2006.02348.x.
Regulatory T cells are proposed to play a central role in the maintenance of immunological tolerance in the periphery, and studies in many animal models demonstrate their capacity to inhibit inflammatory pathologies in vivo. At a recent meeting [Clinical Application of Regulatory T Cells, 7-8 April 2005, Horsham, UK, organized by the authors of this review, in collaboration with the British Society for Immunology and Novartis] evidence was discussed that certain human autoimmune, infectious and allergic diseases are associated with impaired regulatory T-cell function. In contrast, evidence from several human cancer studies and some infections indicates that regulatory T cells may impair the development of protective immunity. Importantly, certain therapies, both those that act non-specifically to reduce inflammation and antigen-specific immunotherapies, may induce or enhance regulatory T-cell function. The purpose of this review was to summarize current knowledge on regulatory T-cell function in human disease, and to assess critically how this can be tailored to suit the therapeutic manipulation of immunity.
调节性T细胞被认为在维持外周免疫耐受中起核心作用，许多动物模型研究证明它们在体内具有抑制炎症性疾病的能力。在最近一次会议上[调节性T细胞的临床应用，2005年4月7 - 8日，英国霍舍姆，由本综述作者组织，与英国免疫学会和诺华公司合作]，讨论了相关证据，即某些人类自身免疫性、感染性和过敏性疾病与调节性T细胞功能受损有关。相反，一些人类癌症研究和某些感染的证据表明，调节性T细胞可能会损害保护性免疫的发展。重要的是，某些疗法，无论是非特异性减轻炎症的疗法还是抗原特异性免疫疗法，都可能诱导或增强调节性T细胞功能。本综述的目的是总结目前关于调节性T细胞在人类疾病中功能的知识，并批判性地评估如何对其进行调整以适应免疫治疗的操作。
